Page last updated: 2024-11-08

nsc 401077

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

NSC 401077: inhibits DNA methyltransferase DNMT1; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID344265
CHEMBL ID383475
SCHEMBL ID562060
MeSH IDM0496164

Synonyms (39)

Synonym
HMS1762H13
STK724063
NCI60_003759
2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-3-(1h-indol-3-yl)propanoic acid
OPREA1_475901
OPREA1_410805
NSC401077 ,
mls000757170 ,
32675-71-1
EU-0040737
smr000413613
2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-3-(1h-indol-3-yl)-propionic acid
MLS000777218
nsc 401077
CHEMBL383475 ,
bdbm50180790
2-(1,3-dioxoisoindolin-2-yl)-3-(1h-indol-3-yl)propanoic acid
AKOS001035895
2-(1,3-dioxoisoindol-2-yl)-3-(1h-indol-3-yl)propanoic acid
HMS2752N14
2-(1,3-dioxo-2,3-dihydro-1h-isoindol-2-yl)-3-(1h-indol-3-yl)propanoic acid
AKOS016340696
SCHEMBL562060
ES-0018
MLS006011919
2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-3-(1h-indol-3-yl)propanoic acid #
HPTXLHAHLXOAKV-UHFFFAOYSA-N
mfcd08705332
SR-01000456137-1
sr-01000456137
Z56804250
SB19339
HMS3426M03
mfcd00379702
CS-0137819
(rac)-rg108
DTXSID501036239
EN300-6493129
F70732
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency55.75610.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
pyruvate kinase PKM isoform aHomo sapiens (human)Potency25.11890.04017.459031.6228AID1631; AID1634
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency100.00000.010323.856763.0957AID2662
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CPG DNA methylaseSpiroplasma monobiaeIC50 (µMol)0.60000.00280.55821.6000AID257910
DNA (cytosine-5)-methyltransferase 1Homo sapiens (human)IC50 (µMol)50.00000.01861.64886.0000AID257909
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA-templated transcriptionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
positive regulation of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
methylationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
epigenetic programming of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cellular response to amino acid stimulusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
chromosomal DNA methylation maintenance following DNA replicationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cellular response to bisphenol ADNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell apoptotic processDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switchingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
DNA bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
RNA bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA (cytosine-5-)-methyltransferase activityDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
protein bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
zinc ion bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
methyl-CpG bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA-methyltransferase activityDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
promoter-specific chromatin bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
female germ cell nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleoplasmDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
replication forkDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
pericentric heterochromatinDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID257909Inhibitory activity against DNA methyl transferase in leukemic NALM6 cells2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Discovery of two novel, small-molecule inhibitors of DNA methylation.
AID461002Inhibition of human recombinant DNMT3B expressed in baculovirus-insect cell system at 100 uM by scintillation counting2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
AID461001Inhibition of human recombinant DNMT1 expressed in baculovirus-insect cell system at 100 uM by scintillation counting2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
AID257910Inhibition of recombinant CpG methylase M.SssI2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Discovery of two novel, small-molecule inhibitors of DNA methylation.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's6 (60.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]